skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration
  • Close Icon
Pharma Intelligence brings you critical pharmaceutical research studies, featuring new pharmaceutical research developments, and delivers them to you in a timely fashion. Rely on the experienced experts from Pharma Intelligence for essential information and unparalleled insights you can use to inform your own business decisions and strategies.

The hits keep coming!

You’ve already tuned into Pharma R&D Annual Review 2018, the free, music-themed whitepaper from Citeline’s Pharmaprojects (which you can still access below). Now, get even more free market data and insights with your download of Pharma R&D Annual Review 2018 Supplement: New Active Substances Launched During 2017.

Examine the most successful new active substances (NASs) that hit the market for the first time in 2017. Find out:
  • Which substances will be in heavy rotation?
  • Which made it to the top of the charts?
  • And which went platinum?
Research and Development

最新の医薬品業界ニュース

  • Generics Bulletin: ジェネリック&バイオシミラーニュース

    Global Industry Hails Bioequivalence Progress

    By Aidan Fry 11 Dec 2019

    For the first time, a working group within the International Council for Harmonization has started work on a regulatory topic specifically tailored to the global generics and biosimilars industry.

  • HBW Insight : コンシューマーヘルスケア産業のニュース

    US Senate Passes First Monograph Reform Bill After House Passed Three

    11 Dec 2019

    Senate's Over-the-Counter Monograph Safety, Innovation, and Reform Act goes next for consideration by House, which has had a bill by the same title on its floor for a vote since it was passed by Energy and Commerce Committee in late June.

  • HBW Insight : コンシューマーヘルスケア産業のニュース

    Fragrance Creators Association Readies New Consumer Website To Cap 'Year For The Public'

    11 Dec 2019

    Farah Ahmed, president and CEO of the Fragrance Creators Association, discusses the trade group’s expansion in recent years beyond immediate regulatory and legislative concerns to a platform for robust member collaboration in the name of positively impacting the world.

  • HBW Insight : コンシューマーヘルスケア産業のニュース

    Future of CBD In Supplements: NDI Notification Looms As Regulatory Path

    06 Dec 2019

    Article

    Recent statement that FDA has not found evidence supporting CBD as GRAS for use in human or animal food potentially points to NDI notifications as the only option manufacturers, marketers and other businesses will have to convince agency about safety for CBD and other hemp-derived substances used in dietary supplements.

  • HBW Insight : コンシューマーヘルスケア産業のニュース

    GSK Launches OTC Fluticasone In Japan Following Switch

    By Tom Gallen 06 Dec 2019

    Article

    GSK has launched Flunase in Japan following the switch of fluticasone propionate. JSMI’s Toshi Tominaga gives his assessment of the product’s prospects as an OTC drug.

  • Generics Bulletin: ジェネリック&バイオシミラーニュース

    Ophthalmics Are Next Frontier For Teligent

    06 Dec 2019

    US niche generics player Teligent intends to use its expertise in topical and injectable drugs manufacturing to push into the North American ophthalmics sector.

  • HBW Insight : コンシューマーヘルスケア産業のニュース

    Sunscreen Industry Faces Major Challenge In GRASE Push That OTC Monograph Reform Would Solve

    28 Nov 2019

    Industry advocates working to support GRASE determinations for eight UV filters are faced with a dilemma. They would like to share nonpublic studies with the FDA on a confidential basis – at least to get initial temperature readings from the agency as to the studies’ usefulness in addressing data gaps – but under the current OTC monograph framework, no such pathway exists.

  • Generics Bulletin: ジェネリック&バイオシミラーニュース

    Celltrion's Remsima SC Ready For Early 2020 Launch

    28 Nov 2019

    Celltrion says it is ready to roll out its Remsima SC subcutaneous infliximab in Europe in the first quarter of 2020, after receiving a formal pan-European marketing authorization from the European Commission.

  • HBW Insight : コンシューマーヘルスケア産業のニュース

    Complicated Regulatory Odyssey Steers FDA Toward Rule On CBD In Supplements

    27 Nov 2019

    Before Congress de-scheduled hemp at end of 2018 and forced agency's hand on considering lawful use of ingredients derived from the plant in supplements and food, the floodgate for sales of the products was opened in 2013 by a DoJ policy change to de-emphasize enforcement of most federal marijuana laws.

  • HBW Insight : コンシューマーヘルスケア産業のニュース

    Aspirational Products Driving Growth In Developed OTC Markets

    22 Nov 2019

    Aspirational OTC products such as probiotics are outstripping demand for traditional symptom relievers, IQVIA's Andy Tisman told the recent Ceuta International Conference. Consumer health players must adapt their portfolios to cater for the more health conscious, informed, and digitally-connected consumer, Tisman advises

    Topic business-strategies

  • Generics Bulletin: ジェネリック&バイオシミラーニュース

    Amneal Starts Seeking International Partners

    20 Nov 2019

    In a bid to make better use of Amneal’s US portfolio and pipeline, the company is looking for international licensing partners, especially in Eastern Europe and China, as its new management team looks to restore growth and revive profit margins.

    Topic Business strategies

  • Generics Bulletin: ジェネリック&バイオシミラーニュース

    Accord Strikes Thiotepa Deal With Adienne

    By Aidan Fry 20 Nov 2019

    Accord Healthcare has secured commercial rights to Adienne’s novel lyophilized formulation of thiotepa in Europe, extending its portfolio of cancer treatments.

    Topic business-strategies cancer

  • HBW Insight : コンシューマーヘルスケア産業のニュース

    Vitamin D, Omega-3 No Help For Diabetics Against CKD, VITAL Data Show

    13 Nov 2019

    In latest study casting doubt on the nutrients' effect on chronic illness, researchers find vitamin D and fish oil ineffective in staving off type 2 diabetics' kidney failure. Editorial also published in JAMA says further research is needed to analyze the nutrients’ possible benefits to diabetics with chronic kidney disease.

    Topic clinical-trials

  • HBW Insight : コンシューマーヘルスケア産業のニュース

    Novartis Wins Second Landmark German Case, This Time For Probiotics

    13 Nov 2019

    Following a landmark win against the German government for the Rx-to-OTC switch of desloratadine last month, Novartis has again secured a victory in the German Higher Court system, this time to continue marketing its Biosan probiotics range in the country.

    Topic company-analysis policy-and-regulation

  • Generics Bulletin: ジェネリック&バイオシミラーニュース

    Aurobindo Is Company Of The Year At GGB Awards

    13 Nov 2019

    Article

    Aurobindo has taken home the awards for Company of the Year and Acquisition of the Year at the Global Generics & Biosimilars Awards 2019, held in Frankfurt, Germany. Accord also received two awards, among a host of other recognized companies.

    Topic biosimilars

Data and analysis products

sitetrove-pharmaintelligence

Sitetrove: 治験責任医師と治験施設情報のデータベース

Sitetrove(サイトトローブ)は、170か国・40万人以上の治験責任医師(PI: Principal Investigator)と235以上の疾患に対応する11万7千か所以上の治験施設に関する情報を収録するデータベースです。治験責任医師と治験施設に関して業界で最も正確で包括的な情報を提供することで、コスト増につながる治験の遅延を最小化し、お客様の臨床試験を成功に導くようサポートします。Sitetroveに登録される治験責任医師は、豊富な臨床経験や治験に関する十分な知識をもっていることをアナリストにより精査されています。

Key benefits:

  • 治験責任医師と治験施設情報のデータベース
  • 疫学ダッシュボードは見やすいマップビュー
  • Ask-the-Analyst機能で情報に基づく意思決定
data-monitor-health-care-pharma intelligence

Datamonitor Healthcare: 医療用医薬品の市場調査レポート

Datamonitor Healthcare(データモニターヘルスケア)では主要な疾患と医薬品をカバーする市場調査レポートを収載し、定期的に更新しています。市場調査レポート1本単位の購入または疾患単位の購読契約による対象の市場調査レポートすべての閲覧が可能です。新医薬品の市場性の評価や研究開発戦略の立案にご利用ください。

Key benefits:

  • 客観的市場調査の力で成長戦略を確かにする
  • 最新市場予測ツールでアンメットニーズ特定
  • Ask-the-Analyst機能で情報に基づく意思決定
pharma intelligence pharma banner

Pharmaprojects: 医薬品開発パイプラインのデータベース

Pharmaprojects(ファーマプロジェクツ)は、医薬品業界で代表的な開発パイプライン(医療用医薬品候補化合物)のデータベースとして、医薬品企業をはじめとする多くのお客様にご利用いただいています。前臨床試験から上市済み医薬品まで、現在開発中の15,000の薬剤を含む68,000以上の開発パイプライン情報を収録しています。さらに、43,000以上の医薬品を網羅した35年間にわたる過去のデータベースにもアクセスできます。グローバル競争が激しくなる中、競合分析や研究開発戦略の策定に威力を発揮するデータベースです。

Key benefits:

  • 医療用医薬品の研究・開発パイプライン情報
  • 35年間にわたる過去のヒストリカルデータも
  • Ask-the-Analyst機能で情報に基づく意思決定

お問い合わせ&レポートストア

専任スタッフによるデモンストレーションを兼ねたサービスの詳しいご説明、または無料トライアルを常時受け付けています。ご希望の場合は下記のフォームよりお気軽にお申し込みください。

*一部のサービスでは無料トライアルをご利用になれません。

ご質問等ございましたらお気軽にご連絡下さい。

日本(平日:9時~18時)
電話:+81 (0)3 6273 4260
Email:inquiry.jp@informa.com

オンラインショップのレポートストアでは、医療用医薬品の市場調査・分析レポートを常時1000本以上販売しています。レポート1本単位で購入でき、オンラインでご提供いたします。

お探しの情報が見つからない場合はお問い合わせ先までお気軽にご連絡ください。